Zomelis SR 100 Tablet

Zomelis SR 100 is indicated as monotherapy or in combination with other antidiabetic agents, including metformin or insulin, for patients inadequately controlled by diet and exercise alone. The sustained-release formulation ensures a prolonged therapeutic effect, allowing once-daily dosing and improved patient compliance. It is essential to monitor renal function periodically during treatment, as dose adjustments may be necessary in patients with renal impairment.

Common adverse effects include headache, dizziness, and mild gastrointestinal disturbances, while serious adverse events are rare. Zomelis SR 100 should be used under medical supervision, with regular monitoring of blood glucose levels to optimize therapy and minimize risks. It is not indicated for type 1 diabetes or diabetic ketoacidosis.